Moving from Policy to Practice in Research and Delivery

This meeting will highlight the changing nature of evidence standards within the marketplace; specifically, the continued push for increased levels of evidence of comparative effectiveness applied within health technology assessments (HTAs). The goal of the meeting is to focus less on definitions and theoretic concepts, and more on the application of comparative effectiveness research (CER) and HTA within drug development and research planning.

While the discussion of CER has been ongoing for years, the recent creation of the Patient-Centered Outcomes Research Institute (PCORI) within health care reform, as well as new standards for evidence evaluation development by leading payers, have made understanding not just the theories, but rather their applications, of vital importance. This meeting will push beyond the basic questions to evaluate the importance of CER and provide participants with actionable understandings of how CER evidence can be better managed and developed within their own organizations.

Unlike previous efforts in this area, this meeting will provide participants with a "what does it mean for me" perspective on CER and HTA, providing take-aways to apply within day-to-day drug development and marketing positions.

Learning Objectives

At the conclusion of this meeting, participants should be able to:

  • Define comparative effectiveness research techniques within their day-today activities
  • Describe how to use internal evidence-generation and application strategies with the specific market sectors they support (e.g., payor markets, providers, etc.)
  • Translate evidence of product effectiveness for best application within multiple market settings

Who Should Attend

  • HEOR/Phase III/IIIb Researchers within pharmaceutical companies
  • Medical Affairs/Health Outcomes Liaisons within pharmaceutical companies
  • Researchers/Analysts within payers with responsibility for evidence collection, analysis, and/or decision making
  • Health policy personnel, researchers, federal or state government employees, and private sector employees

Event Information

Melissa Matta, Program Developer
Phone +1.215.442.6158, Fax +1.215.442.6199, email Melissa.Matta@diahome.org

Tabletop Exhibits Information

Jeff Korn, Worldwide Exhibits Associate
Phone +1.215.442.6184, Fax +1.215.442.6199, email: Jeff.Korn@diahome.org

Committee & Speakers

Program Committee

Craig A. HunterPROGRAM CHAIRPERSON
Craig A. Hunter, MPP, PGDP

Senior Research Scientist
Eli Lilly and Company
View Biography

Craig A. Hunter, MPP, PGDP, brings over a decade of experience in health outcomes research, strategic evidence planning, government policy, and market access/reimbursement for the pharmaceutical, biotech, and device communities, including expertise in methods and applications related to comparative effectiveness, health technology assessment, and risk-sharing agreements/patient access schemes.  In his current role, Craig is responsible for the planning and execution of phase IIIb/IV health outcomes and economic research plans and studies for Lilly’s Oncology and Alzheimer’s disease products in the US.

Prior to joining Eli Lilly, Craig was the Vice President for Policy and Reimbursement at the Neocure Group, working in support of medical and biotechnology companies.  Within this role, Craig was responsible for ensuring clients were well-prepared evidentially for regulatory and reimbursement challenges associated with new product commercialization. In a similar previous role, Craig served as the Senior Manager for Science Policy with the United BioSource Corporation (UBC), in which helped to create and lead the science policy group’s activities through the design, management, and analysis of health policy and economic impact projects for a broad range of both pharmaceutical and device clients. Craig has also worked as a consultant with Thomson Medstat, supporting AHRQ and SAMHSA research projects, as well as serving as a Primary Investigator for the U.S. Agency for International Development (USAID) in South Africa.

Trained in public policy, research, management, and demography, Hunter holds a Masters of Public Policy from the University of Chicago; a Post-Graduate Diploma in Population Studies (Demography) from University of KwaZulu-Natal, South Africa; and a Bachelor of Arts in Political Science and Communications/Rhetoric from Furman University.

Robert W. DuboisRobert W. Dubois, MD, PhD
Chief Science Officer
National Pharmaceutical Council
View Biography

Robert W. Dubois, MD, PhD, joined the National Pharmaceutical Council in October 2010 as its Chief Science Officer. In this role, he oversees NPC’s research on policy issues related to comparative effectiveness research, as well as on how health outcomes are valued.

Dr. Dubois, a board certified in internal medicine, brings more than 25 years of experience in health services research and comparative clinical effectiveness. He co-founded and led various health care research organizations in developing quality research with practical application. Most recently, he was the chief medical officer at Cerner LifeSciences, where he focused on comparative effectiveness and the use of an electronic health records infrastructure to implement clinical change.

Prior to joining Cerner in 2001, Dr. Dubois co-founded Protocare Sciences and was its executive vice president, chief medical officer, and later its chief executive officer.

Throughout his career, Dr. Dubois’ primary interest has centered on defining “what works” in health care and finding ways for that evidence to inform health care decision making. He is a recognized expert in the areas of defining best practice, disease management and appropriateness of care. He has authored more than 100 peer-reviewed articles on comparative effectiveness, evidence-based medicine, the development of practice guidelines and determining the optimal use of high-cost medical services.
Ross MacleanRoss Maclean, MD
Vice President Health Services, The Americas
Bristol-Myers Squibb Company
View Biography

Ross Maclean, MD, is a UK-trained physician and health services researcher. From 1990-2002 he held a variety of posts in academia in the UK and US. In 2002, Dr. Maclean joined Bristol Myers Squibb; currently he is Vice President for Health Services across The Americas where his remit is to deliver health economic and outcomes research evidence that supports access and appropriate use, and is aligned with the healthcare quality priorities of patients, providers and payer customers. He has published widely in the areas of healthcare quality, health economics and health services research.

Sean D. SullivanSean D. Sullivan, PhD
Professor of Pharmacy and Public Health
Director, Pharmaceutical Outcomes Research and Policy Program
Associate Dean for Research, School of Pharmacy University of Washington
View Biography

Sean D. Sullivan, BScPharm, MSc, PhD, is Professor and Associate Dean for Research at the University of Washington School of Pharmacy. He holds a joint appointment as Professor of Health Services in the School of Public Health, is Director of the UW Pharmaceutical Outcomes Research and Policy Program (PORPP) and co-Director of the University of Washington Centers for Comparative and Health Systems Effectiveness (CHASE Alliance). He holds adjunct appointments in the School of Medicine, the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, and at Group Health Research Institute.

Dr. Sullivan completed his bachelor's degree in pharmacy from Oregon State University in 1983, master's degree in administrative and economic sciences from the University of Texas in 1986 and PhD in health economics and policy from the University of California-Berkeley in 1991.

He has authored more than 300 journal articles, book chapters, task force reports and organizational and governmental publications. In many of these writings, he has assessed the evidence and applications of medical technology in relation to coverage and reimbursement decisions. His research interests include technology assessment, medical decision-making and economic evaluation of medical technology. He is the past chair of the Academy of Managed Care Pharmacy executive committee on the AMCP Format for Formulary Submissions - the United States evidence-based guidelines for formulary decision-making.

Dr. Sullivan is a member of the Medicare Evidence Development and Coverage Advisory Committee. He is also on the editorial boards of Value in Health, PharmacoEconomics, European Journal of Health Economics and Core Evidence. He is a past president of the International Society for Pharmacoeconomics and Outcomes Research.

Program Speakers

Bart Barefoot Bart Barefoot
Director, Public Policy
GlaxoSmithKline
View Biography

Bart Barefoot is a Director of Public Policy at GlaxoSmithKline (GSK) in Research Triangle Park, North Carolina, where he is responsible for policy position development and legislative and regulatory strategies for a broad range of issues at the federal and state levels, including comparative effectiveness research.

Prior to joining GSK in 2004, Bart practiced health care law at Hogan & Hartson LLP (now Hogan Lovells) in Washington DC, where he advised biopharmaceutical, medical device, and hospital system clients on health care regulatory matters, including Medicare, Medicaid, privacy, and human subject research protection laws.  Previously, he worked on health policy and privacy issues for IBM Federal Government Relations.

Bart was educated at Duke University and the University of North Carolina at Chapel Hill School of Law.

Anirban Basu, PhD Anirban Basu, PhD
Associate Professor, Dept. of Health Services, School of Public Health
Adjunct Associate Professor
Pharmaceutical Outcomes Research and Policy Program (PORPP)
University of Washington, Seattle
View Biography

Dr. Basu is an associate professor in the Departments of Health Services and Pharmacy at the University of Washington, Seattle. He is also a faculty research fellow at the National Bureau of Economic Research. Dr. Basu received his MS in Biostatistics from the University of North Carolina, Chapel Hill in 1999 and his PhD in Public Policy from the University of Chicago in 2004.

Dr. Basu's research interests lie in revealing heterogeneity in clinical and economic outcomes in order to establish the value of individualized care. His work has focused on translating such information for public policy using innovative methods in comparative effectiveness and cost-effectiveness research. Dr. Basu has developed methods dealing with issues related to modeling health expenditure data, which is renowned for its idiosyncrasies and the difficulties it poses for applied health services researchers. He has also worked on methods used for making causal inferences using observational data. His applied work spans many dimensions that include analyzing the cost-effectiveness of prostate cancer treatments, establishing the value of individualized care based on patient preferences, developing models to predict quality of life of patients with multiple comorbidities, measuring the effect of patients’ health on the quality of life of their partners, developing novel methods to estimate long-term costs of prostate cancer therapies, estimating the future value of research in diagnosing and finding a cure for Duchenne muscular dystrophy, developing simulation models for evaluating the cost-effectiveness of pharmacological treatment algorithms in schizophrenia, and  comparative effectiveness research on the dynamic intensification of glucose lowering therapies in diabetes.

Dr. Basu is an Associate Editor for both Health Economics and the Journal of Health Economics and has taught courses on decision analysis, cost-effectiveness analysis and health services research methods. He has received numerous recognitions for his work throughout his career and for which he remains grateful to his mentors and peers:  the NARSAD Wodecroft Young Investigator Award (2005), the Research Excellence Award for Methodological Excellence (2007) and the Bernie O’Brien New Investigator Award (2009) from the International Society for Pharmacoeconomics and Outcomes Research, the Alan Williams Health Economics Fellowship (2008) from the University of York, UK and the Labelle Lectureship in Health Economics (2009) from McMaster University, Canada.

Marc L. Berger, MD Marc Berger, MD
Executive Vice President & Senior Scientist, Life Sciences
OptumInsight
View Biography

Marc L. Berger, MD, is executive vice president and senior scientist in the Life Sciences group at Ingenix, a part of Optum. A native of New York, he has held senior positions in the pharmaceutical industry including Vice President, Outcomes Research and Management at Merck & Co., Inc. from 2002 – 2007, and Vice President, Global Health Outcomes, at Eli Lilly and Company from 2007 - 2011.

He obtained an MD degree from Johns Hopkins University School of Medicine and has held adjunct appointments as Senior Fellow at the Leonard Davis Institute at the Wharton School of the University of Pennsylvania and Professor in the Department of Health Policy and Administration at the University of North Carolina at Chapel Hill School of Public Health. He has served on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for the Center for Medicare & Medicaid Services (CMS), the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the steering committee for the Agency for Health Care Research and Quality (AHRQ) Centers for Research and Education on Therapeutics (CERTs), and the board of the Health Industry Forum of the Heller School for Social Policy and Management at Brandeis University. Currently, he is a member of the editorial advisory board ofValue in Health. Marc has published widely in peer-reviewed journals in health services research, outcomes research, health economics, and health policy.

Lorrie CarrLorrie Carr, MBA
Senior Director, US Market Access
Millennium Pharmaceuticals: The Takeda Oncology Company
View Biography

Lorrie Carr is currently head of US Market Access for Millennium Pharmaceuticals.  Lorrie leads a team she built of National, Regional and Federal field Account managers who work with government and private payers, State Societies, oncology practices and other stakeholders to ensure appropriate access to Millennium’s cancer medications.  In addition Lorrie is responsible for bringing together cross-functional teams within Millennium in order to ensure that the company is prepared for the changing health care environment as it relates to oncology reimbursement (patient and payer impacts), CER, ACO’s, and value-based healthcare.

Lorrie started her career in healthcare working in the physician practice management setting for North American Medical Management.  She has significant experience within a start-up PHO/IPA, and as the head of Network Development, Lorrie implemented and managed some of the early capitated contracts between Physicians and Health Plans.

Just prior to joining Millennium, Lorrie was the Director of Managed Care Marketing for Schering-Plough Corporation (now Merck).  Building value propositions for payers within crowded categories of drugs was a critical component of her job.  Lorrie received her MBA from the Isenberg School of Management at UMASS.

James D. Chambers James D. Chambers, PhD, MPharm, MSc
Project Director
The Center for the Evaluation of Value and Risk in Health
The Institute for Clinical Research and Health Policy Studies
Tufts Medical Center
View Biography

Dr. Chambers is a Project Director at the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center. He leads and works on projects associated with the use of cost-effectiveness evidence in the US health care system.  James also helps maintain the Tufts Medical Center Medicare National Coverage Determinations (NCD) database. Previously, James worked as a Senior Research Manager at Mapi Values, a pharmaceutical consultancy firm based in Boston. During his four years at Mapi Values, including one year in the UK office, James worked on a variety of projects including those pertaining to health economic modeling and evidence synthesis.

James graduated from Queens University in Belfast with an MPharm degree and previously worked as a pharmacist in the UK and Ireland. He also obtained an MSc from the University of York and PhD from Brunel University, both in Health Economics. James' research interests include what factors influence Medicare coverage decisions and the use, and potential value, of cost-effectiveness in the U.S. health care system.

Sherine Gabriel, MD, MSc Sherine Gabriel, MD, MSc
Chair, Methodology Committee
Patient-Centered Outcomes Research Institute (PCORI)
Professor of Medicine and of Epidemiology
Mayo Clinic
View Biography

Dr. Gabriel is Professor of Medicine (Rheumatology) & Professor of Epidemiology, and the William J. and Charles H. Mayo Endowed Professor.  After her appointment, by the U.S. Government Accountability Office to the Methodology Committee of the Patient Centered Outcomes Research Institute (PCORI), she became its first Chair. She is also Co-Principal Investigator and Director of Education, Mayo Clinic Center for Clinical & Translational Sciences (CTSA); and is a Past President of the American College of Rheumatology.

Dr. Gabriel’s research, which is largely NIH funded, has resulted in more than 200 peer-reviewed scientific publications addressing the risks, costs, determinants, and outcomes of the rheumatic diseases. She has received numerous research awards in recognition of these contributions.

Dr. Gabriel earned a Doctor of Medicine degree, with distinction, from the University of Saskatchewan, Canada, completed Internal Medicine Residency and Rheumatology fellowship at Mayo Graduate School of Medicine and a Master of Science in Clinical Epidemiology from McMaster University. She is certified by the American Board of Internal Medicine in Internal Medicine and in Rheumatology. 

Teresa B. Gibson, PhD Teresa B. Gibson, PhD
Director of Health Outcomes
Thomson Reuters
View Biography

Dr. Gibson, director of health outcomes at Thomson Reuters is responsible for research and development activities focusing on applications of econometric, statistical, and analytic methods to administrative data and healthcare datasets.

Among the topics addressed in Dr. Gibson’s research and publications are chronic illness, prescription drug utilization, financial incentives, and managed care. She has focused on the role of patient cost-sharing in the treatment of chronic illness. Dr. Gibson has considerable experience with administrative data sets and serves as task leader for the outpatient database development effort on the AHRQ-funded Healthcare Cost and Utilization Project (HCUP) and has served as project director for several DoD-funded studies of healthcare utilization and spending.

Previously, Dr. Gibson held management and analytic positions in the MarketScan® and Medstat Systems divisions of Medstat – now Thomson Reuters. Notably, she directed the development, maintenance, and delivery of Medstat’s MarketScan Databases and has developed expertise in analyzing and evaluating the healthcare experience of privately insured individuals. On occasion, Dr. Gibson serves as a Lecturer in the University of Michigan School of Public Health Department of Health Policy and Management where she teaches quantitative methods in the residential master’s degree program.

She received a PhD in Health Services Organization and Policy and a master’s degree in Economics, both from the University of Michigan. She holds a master’s degree in Health Administration and Industrial Engineering from the University of Michigan and a bachelor’s degree in Mathematics from Carnegie Mellon University.

Jordan Goldberg Jordan Goldberg
CEO
stickK.com, LLC
View Biography

Jordan Goldberg is the co-founder and CEO of stickK.com, a goal-setting website based on behavioral economics research conducted by co-founders and Yale economists Ian Ayres (author of 11 books including NYTimes bestseller Super Crunchers and the most recent Carrots and Sticks, Fall 2010) and Dean Karlan (President, Innovations for Poverty Action). The website allows the public to utilize incentives and accountability to encourage behavior change, primarily in the health and wellness space.

Jordan’s experience places him at the forefront of applied behavioral economics harnessing social media trends, gaming and technology with the power of incentives and layers of social/professional accountability to help individuals create lasting change. In December 2009, stickK began offering customized versions of its goal-setting platform to meet the specific needs of corporations including, but not limited to, employee wellness, innovative consumer engagement, energy, and financial goals.

Jordan has been frequently interviewed for print, television and on-line media, appearing on NBC’s TODAY Show and CBS News Sunday Morning, as well as The Wall Street JournalThe New York Times, and The Economist. He has also been a featured speaker at numerous professional events, including the Penn- CMU Annual Symposium on Health and Behavioral Economics, the CDC’s annual conference on Health Communication, Marketing, and Media, the World Research Group’s conference on ROI for Wellness, the Harvard, Wharton and Yale Healthcare Business Conferences, and the annual conference for NARUC (National Association of Regulatory Utility Commissioners).

His prior experience includes founding another internet startup and consulting in real estate development and healthcare advocacy. A graduate of Yale University with a bachelor’s degree in American Studies, Jordan is also a recipient of the Yale School of Management’s Silver Anniversary Scholarship and is a 2007 fellow at the Yale Entrepreneurial Institute.

Sheldon GreenfieldSheldon Greenfield, MD
Executive Co-Director
Health Policy Research Institute
University of California, Irvine
View Biography

Sheldon Greenfield, MD, is the Donald Bren Professor of Medicine and co-executive director of the Health Policy Research Institute at the University of California, Irvine. Dr. Greenfield recently chaired a national Institute of Medicine committee that issued two reports offering guidance to healthcare providers in evaluating various healthcare options. The first report, "Clinical Practice Guidelines We Can Trust," recommends eight standards to ensure the objective, transparent development of trustworthy clinical practice guidelines. The second, "Finding What Works in Health Care: Standards for Systematic Reviews," recommends 21 standards to ensure objective, transparent and scientifically valid reviews. Poor-quality reviews can lead clinicians to the wrong conclusions and, ultimately, to inappropriate treatment decisions, the IOM panel noted.

Gail Gibson HuntGail Gibson Hunt
President and CEO
National Alliance for Caregiving
View Biography

Gail Hunt is President and CEO of the National Alliance for Caregiving, a non-profit coalition dedicated to conducting research and developing national programs for family caregivers and the professionals who serve them.  Prior to heading NAC, Ms. Hunt was President of her own aging services consulting firm for 14 years.  She conducted corporate eldercare research for the National Institute on Aging and the Social Security Administration, developed training for caregivers with AARP and the American Occupational Therapy Association, and designed a corporate eldercare program for EAPs with the Employee Assistance Professional Association.  Prior to having her own firm, she was Senior Manager of human services for the Washington, DC, office of KPMG Peat Marwick.  Ms. Hunt attended Vassar College and graduated from Columbia University in New York.  She was appointed by the White House to serve on the Policy Committee for the 2005 White House Conference on Aging. Ms. Hunt was on the Advisory Panel on Medicare Education, is chair of the National Center on Senior Transportation, is a Commissioner of the Center for Aging Service Technology, and  is Secretary of the Long-Term Quality Alliance.  Additionally, Ms. Hunt is on the Governing Board of the Patient-Centered Outcomes Research Institute (PCORI).

Gilbert J. L'ItalienGilbert J. L’Italien, PhD
Executive Director, Global Health Economics and Outcomes Research
Bristol Myers Squibb
Adjunct Assistant Professor
Yale University School of Medicine
View Biography

Dr. L’Italien currently leads the Immunology, Neurosciences and Virology divisions in the Global Health Economics and Outcomes Research Department at Bristol Myers Squibb. An epidemiologist and biostatistician by training, Gil brings over twenty years of observational research experience to his role and he has published and presented extensively in the clinical, pharmacoepidemiology and health outcomes fields. Gil is also Adjunct Assistant Professor at Yale University Medical School and Affiliated Faculty member for the Robert Wood Johnson Clinical Scholars Program at Yale.

In 2003, he received the Bristol Myers Squibb Ondetti and Cushman Award for creation of a database function unique to the pharmaceutical industry. In 2006, he received the Bristol-Myers Squibb Distinction Award for design and conduct of the first BMS comparative effectiveness trial (STAR) of antipsychotic treatments in schrizophrenia patients. This study and others contributed to the public health awareness of heightened cardiometabolic risk in psychiatric populations. In 2003 Gil served as Vice President, Pharmacoepidemiology for I3Innovus.

In 2008, Gil was appointed to the Steering Committee, Center for Education and Research on Therapeutics (CERT), Agency for Health Care Research and Quality (AHRQ), US Department of Health and Human Services. He is also a member of the National Pharmacy Council, representing Global Health Outcomes Research for Bristol-Myers Squibb. In addition to his disease area responsibilities, his current research interests focus on use of large scale databases for comparative effectiveness research, predictive modeling, and the application of prognostic and diagnostic biomarkers to clinical development and real world research

David Kent, MD, MSC David Kent, MD, MSC
Associate Professor of Medicine
Institute for Clinical Research and Healthy Policy Studies
Tufts Medical Center
View Biography

Dr. Kent is a Clinical Investigator in the Institute for Clinical Research and Health Policy Studies as well as an attending physician in Internal Medicine at Tufts Medical Center. His principal research interest is in the clinical importance of outcome-risk and treatment-effect heterogeneity in clinical trials, and his research has focused primarily on cardiovascular and cerebrovascular disease. He is currently PI of the NINDS-sponsored Risk of Paradoixical Embolism (RoPE) Study,a multinational study to determine how to select from patients presenting with cryptogenic stroke those likely to benefit from closure of a patent foramen ovale, and he also is PI and Co-PI of two R21 AHRQ-sponsored R21 grants focused on the complex patient with multimorbidity. The common theme of these projects is that the average results of clinical trials do not apply to all patients, even those meeting trial inclusion criteria. Dr Kent has advocated a risk modeling approach to trial analysis that would permit better tailoring of results to individual patients, while minimizing the well known risks of multiple subgroup analysis. To more widely promote this patient-specific, evidence-based approach, Dr Kent directs the Predictive Medicine Component of the Tufts-CTSI.

In addition, a major portion of his time is devoted to educational activities. He is Associate Director of Clinical Research Fellowships at the Institute and Associate Director for the MS/PhD Clinical Research Program at the Sackler School for Graduate Biomedical Studies. He directs the K12 Career Development Program of the Tufts-CTSI. He teaches Study Design, Predictive Modeling and Introduction to Clinical Care Research. He has extensive peer review experience. He is a five year member of the Scientific Review Committee of Tufts Medical Center, and he has sat on various scientific grant review committees for the NIH/NINDS, VA Cooperative Studies Program, medical foundations and foreign governments. He is Associate Editor of the journal Trials and Deputy Editor of the Journal of General Internal Medicine. Dr Kent received his MD at McGill University and received an MSc in Clinical Research Design and Statistical Analysis from the University of Michigan, where he was a Robert Wood Johnson Clinical Scholar.

Bryan R. LuceBryan R. Luce, PhD, MBA
Senior Vice President, Science Policy
United BioSource Corporation
View Biography

Bryan R. Luce, PhD, MBA, is Senior Vice President, Science Policy for United BioSource Corporation (UBC). Dr. Luce founded MEDTAP® International (now part of UBC), serving as its Chairman, President, and CEO until 2002. Previously, he held positions as Director of Battelle’s Centers for Public Health Research and Evaluation, Director of the Office of Research and Demonstrations, Centers for Medicare and Medicaid Services, and Senior Analyst, Office of Technology Assessment (OTA) of the United States Congress.

Dr. Luce is a consultant to numerous government agencies as well as pharmaceutical and device firms worldwide, a member or chair of socioeconomic and public health policy advisory boards for several leading pharmaceutical companies, and recently was a member of the Medicare Evidence Development & Coverage Advisory Committee (MedCAC). He is a Senior Scholar with the Department of Health Policy, Jefferson Medical College and has authored more than ninety scientific publications, including three textbooks on technology assessment, health policy, and cost-effectiveness analysis. In 2008, Dr. Luce founded the Pragmatic Approaches to Comparative Effectiveness (PACE) Initiative whose mission is to explore novel analytical efficiency comparative effectiveness trial methods. Previously, he founded the Bayesian Initiative in Health Economics and Outcomes Research.

He is a Past President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and, in 2008, received the Society’s Avedis Donabedian Outcomes Research Lifetime Achievement Award. A former Special Forces Officer, Dr. Luce holds the rank as Lieutenant Colonel (Retired), Medical Service Corps, US Army Reserves. His undergraduate and master’s training were at the Universities of Vermont and Massachusetts at Amherst. He received his doctorate from the School of Public Health at the University of California at Los Angeles (UCLA).

Chris Marrone Chris Marrone
Outcomes Liaison Consultant
Eli Lilly and Company
View Biography

Chris Marrone graduated with a BS in Pharmacy from Rutgers University, and a PharmD from the University of Texas at Austin. He completed a Pharmacy Practice Residency at Fletcher Allen Health Care in Burlington, VT, and a Drug Information Specialty Residency with Eli Lilly and Company and Purdue University. Chris spent two years at Lilly working as a Global Medical Information Administrator, before moving into various field-medical roles interacting with and providing medical information to external customers. Chris spent over 6 years at Lilly as a Medical Liaison; the first five years in Critical Care and the remaining year and a half in Oncology. Chris has spent the past four years in a Managed Care Outcomes Liaison role at Lilly where he currently focuses on National Accounts. Chris has been active within the Drug Information Association, conducting and publishing various Field Medical surveys and serving as track co-chair for the CER/HTA track of the DIA Annual Meeting.

James F. MurrayJames F. Murray
Senior Director
Global Health Outcomes Center of Expertise
Eli Lilly and Company
View Biography

Dr. Murray is a Research Fellow within Lilly's Global Health Outcomes (GHO) Center of Expertise (COE). The GHO COE is a multi-disciplinary group that supports the other functions within GHO and Lilly in the development and commercialization of Lilly products. He provides expertise and scientific support for the following topics within the COE.

  • Heterogeneity Analysis -research into which phenotypic variables and patient reported measures are useful in predicting which patients will respond to which treatments,
  • Observational and Pragmatic Study Design - provide consultation and review for innovative real world studies that produce evidence on the comparative effectiveness of treatments or the effectiveness of various treatment paradigms,
  • Health Policy - conduct research on key policy issues in conjunction with Global Public Policy colleagues.

Previously, Jim was Executive Director at Merck and Co., in the US Outcomes Research (USOR) group. He was primarily responsible for US health policy research and was the outcomes lead in the strategic development and innovation of Merck's new commercial model launched in 2007. Jim also had a five-year HR rotation at Merck as head of Global Benefits with responsibility for the strategic design, contracting and management of all of Merck's global health and welfare benefits. Jim has a Masters in Information Systems and a PhD in Decision Sciences and Operations Research both from the University of Wisconsin Madison.

Peter Neumann Peter Neumann, ScD
Professor of Medicine
Institute for Clinical Research and Healthy Policy Studies
Tufts Medical Center
View Biography

Peter J. Neumann, ScD, is Director of the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. His research focuses on the use of cost-effectiveness analysis in health care decision making. He is the founder and director of the Cost-Effectiveness Registry (www.cearegistry.org), a comprehensive database of cost-effectiveness analyses in health care.

 Dr. Neumann has also contributed to the literature on the use of willingness to pay and quality-adjusted life years (QALYs) in valuing health benefits and has written widely about regulatory and reimbursement issues. He is the author or co-author of over 175 papers in the medical literature and Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005). Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He received his doctorate in health policy and management from the Harvard University.

Matthew RousculpMatt Rousculp, PhD, MPH
Director, Comparative Effectiveness Research
US Health OutcomesGlaxoSmithKline
View Biography

Matthew Rousculp, PhD, MPH, is the Senior Director of Comparative Effectiveness Research & Health Policy Research at GlaxoSmithKline.  Dr. Rousculp has over 10 years of industry experience in pharmaceuticals and biologics, including U.S. and global focused roles.  Prior to that, Matt was part of various federally funded research centers including the Lister Hill Center for Health Policy and the UAB Injury Control Research Center.

Matt completed his undergraduate studies in Biological Sciences at Rutgers University. He received his MPH in Epidemiology and his PhD in Administration – Health Services from The University of Alabama at Birmingham. Matt has published over 40 manuscripts and book chapters in the area of comparative effectiveness research, health services research, disease burden, and economics including papers in JAMA, Journal of American Geriatrics Society,Value in Health, and Academy of Management Executive.

Matt currently serves on the Health Science Task Force on Good Research Practices – Modeling Studies for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and on the Core Committee on Evidence Based Medicine for DIA, including serving as the past Chair for the Comparative Effectiveness Research track at the DIA Annual Meeting. He has served as an adjunct faculty member at The Indiana University School of Medicine and in the School of Health Related Professions at The University of Alabama at Birmingham.

Dr. Phillip Ruff Philip Ruff, PhD, CChem, MRSC, Csci
Global Pricing & Market Access
Millennium Pharmaceuticals: The Takeda Oncology Company
View Biography

Dr. Ruff holds a BSc in Chemistry from the University of Leicester UK, and a PhD in Applied Spectroscopy, also from the University of Leicester. Additionally, he is a Chartered Chemist and Member of Royal Society of Chemistry (CChem MRSC) and holds the European Union Chartered Scientist designation (CSci).

Prior to leaving the UK, he was commercial head of Medeval, the UK’s largest phase I CRO. Medeval was acquired by ICON Clinical Research in 2003.

In 2004, Phil moved to the US and joined Abbott Laboratories in a policy role, where he initiated and led the Evidence-based Medicine policy initiative, representing Abbott on several PhRMA committees. He also led several health economics/payer/policy advisory boards, looking at evidence development, resulting in significant changes at a strategic development level.

In 2007, Phil joined the Global Pricing and Payer Planning group at Amgen. He was responsible for the development and implementation of an internal HTA/CER resource center, and was part of the Amgen team that implemented CER readiness for both its marketed and pipeline products. He was also responsible for the development of several pipeline molecules, ensuring that appropriate evidence packages were developed to satisfy payer requirements.

In 2011, Phil joined Millennium Pharmaceuticals as part of the Global Pricing and Market Access team, focusing on the development of its emerging pipeline. He has also been instrumental in the creation and implementation of policies and procedures for global price strategy development and governance.

Phil currently resides in Lexington, MA with his family, where the irony of a Brit living in the birthplace of the American Revolution is not lost on him.

Joe V. Selby, MD, MPH Joe V. Selby, MD, MPH
Executive Director
Patient-Centered Outcomes Research Institute (PCORI)
View Biography

Dr. Selby is the first Executive Director of the Patient-Centered Outcomes Research Institute (PCORI). A family physician, clinical epidemiologist and health services researcher, he has more than 35 years of experience in patient care, research and administration.

Selby joined PCORI from Kaiser Permanente, Northern California, where he was Director of the Division of Research for 13 years and oversaw a department of more than 50 investigators and 500 research staff working on more than 250 ongoing studies. He was with Kaiser Permanente for 27 years. An accomplished researcher, Selby has authored more than 200 peer-reviewed articles and continues to conduct research, primarily in the areas of diabetes outcomes and quality improvement. His publications cover a spectrum of topics, including effectiveness studies of colorectal cancer screening strategies; treatment effectiveness, population management and disparities in diabetes mellitus; primary care delivery and quality measurement.

Selby was elected to membership in the Institute of Medicine in 2009 and was a member of the Agency for Healthcare Research and Quality study section for Health Care Quality and Effectiveness from 1999-2003. A native of Fulton, MO, Selby received his medical degree from Northwestern University and his master’s in public health from the University of California, Berkeley. He was a commissioned officer in the Public Health Service from 1976-1983 and received the Commissioned Officer’s Award in 1981.

He serves as Lecturer in the Department of Epidemiology and Biostatistics, University of California, San Francisco School of Medicine, and as a Consulting Professor, Health Research and Policy, Stanford University School of Medicine.

Jody Sheehan Garey, PharmD
Sr. Manager, Oncology Content, Clinical Content & Services
McKesson Specialty Health

Brian SweetBrian Sweet, RPh, MBA
Executive Director
Health Care Alliances
AstraZeneca Pharmaceuticals
View Biography

Brian Sweet, RPh, MBA, Executive Director, Health Care Alliances, AstraZeneca Pharmaceuticals, L.P. Brian is focused on AstraZeneca’s initiatives in real world evidence and comparative effectiveness research and collaborating with health plans, pharmacy benefit managers, and a variety of key business partners. In addition, he coordinates with managed markets customers on the development of performance-driven models, health improvement programs, value-based insurance designs, and evolving healthcare reform issues.

Brian is the former Chief Pharmacy Officer of WellPoint, Inc., a 34 million member Health Benefits Company located in Indianapolis, Indiana. Brian was responsible for overseeing all Clinical Pharmacy Services at WellPoint including leading the National Pharmacy and Therapeutics Committee, which uses integrated data analyses and total cost of care modeling to improve patient health outcomes. In addition, he oversaw the development of strategic pharmacy alliances with academia, government, health organizations, and pharmaceutical companies for the purpose of working together to promote the effective and appropriate use of drugs in the communities that WellPoint serves. Brian provided strategic leadership for establishing enterprise pharmacy programs as an integral part of the organization in developing corporate pharmacy policy and innovative pharmacy benefit designs. He was also responsible for influencing public policy by communicating with media, analysts, professional organizations, members and providers to provide: public policy, legislative, and media responses related to pharmacy coverage, benefits, medication management, the WellPoint Outcomes-Based Formulary application, and specialty pharmacy initiatives.

Tamar R. Thompson Tamar R. Thompson
Group Vice President, Valuebased Purchasing & Health Policy
Jeffrey J. Kimbell & Associates
View Biography

Ms. Thompson is a health policy and reimbursement strategist with extensive experience working with governmental agencies, private payers, Congressional leaders, and patient advocacy groups to improve patient access to existing and new medical therapies. She has more than 10 years of leadership experience in health care, including the ability to develop strategic and tactical recommendations to ensure optimal reimbursement for products.

Prior to joining Kimbell & Associates, Tamar was a senior manager at Avalere Health, where she managed a diverse portfolio of clients, including medical device, biotech, pharmaceutical, and specialty drug companies. Preceding her work with Avalere, Ms. Thompson was Director of Health Policy & Reimbursement at Molecular Insight Pharmaceuticals (MIP), a Kimbell & Associates client.  At MIP, she was charged with developing and launching reimbursement strategy for cutting-edge molecular treatments. Ms. Thompson has also worked for Bracco Diagnostics and GE Healthcare.

Ms. Thompson holds a MS in Health Sciences with a concentration in Public Health.  She also has active certifications from the American Health Information Management Association (AHIMA) as a Certified Coding Specialist (CCS) and Certified Coding Specialist – Physician Based (CCS-P).

Tamar currently serves as co-chairman for the Women in Government Relations (WGR) health and social policies task force, and holds a seat on AHIMA's quality initiatives councils, and the American Association of Medical Society Executives (AAMSE) trends task force.  

Sean TunisSean Tunis, MD, MSc
Founder and Director
Center for Medical Technology Policy
View Biography

Sean Tunis, MD, MSc, is the Founder and Director of the Center for Medical Technology Policy (CMTP) in Baltimore, Maryland. CMTP’s main objective is to improve the quality, relevance and efficiency of clinical research by providing a neutral forum for collaboration among experts, stakeholders and decision makers. Dr. Tunis was a member of the Institute of Medicine Committee on Initial National Priorities for Comparative Effectiveness Research. He advises a wide range of domestic and international public and private health care organizations on issues of comparative effectiveness, evidence based medicine, clinical research, reimbursement and health technology policy.

Through September of 2005, Dr. Tunis was the Chief Medical Officer at the Centers for Medicare and Medicaid Services (CMS), where he had lead responsibility for clinical policy for the Medicare and Medicaid programs. Previously he served as the Director of the Health Program at the Congressional Office of Technology Assessment and as a health policy advisor to the U.S. Senate, where he worked on pharmaceutical and device policy issues.

Dr. Tunis trained at the University of California in Los Angeles and the University of Maryland in Internal Medicine and Emergency Medicine, and holds adjunct faculty positions at the Center for Health Policy at Stanford University, the Department of Internal Medicine at the Johns Hopkins School of Medicine, and the Department of Surgery at the University of California at San Francisco.

Fiona Wilmot, MD, MPH
Vice President
Avalere Health
View Biography

Fiona Wilmot MD MPH is a Vice President in the Evidence-based Medicine and Reimbursement Practices. Dr. Wilmot has over 20 years of experience in managed care with a focus on technology assessment, comparative effectiveness and formulary design.

For over 6 years, Dr. Wilmot served as the Medical Director of Policy, Pharmacy and Therapeutics for Blue Shield of California where she established medical and pharmaceutical coverage policies for 2.7 million covered lives. Additionally, she managed the Transplant Center of Excellence Program and served as liaison with California state regulators around the use of evidence in decision making as well as beneficiary appeals and grievances. Dr. Wilmot has served as Medical Director at Aetna and at a Northern California IPA. Her clinical experience includes working as a hospitalist as well as caring for patients a busy Internal Medicine practice. She has taught Medicine at the University of California San Francisco and is a frequent speaker and facilitator on healthcare business and policy issues. Prior to joining Avalere, Dr. Wilmot was an independent consultant assisting life science clients with navigating market access in commercial health plans.

Dr. Wilmot graduated from Stanford University with distinction in English Literature, and earned her medical degree from the Boston University School of Medicine. She received an MPH from the University of California Berkeley and completed her Internal Medicine training at Mt Zion/UCSF in San Francisco. Dr Wilmot is Board Certified in Internal Medicine.

Continuing Education

Continuing Education Credits

ACPEThe Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a pro vider of continuing pharmacy education. This program is designated for up to 14 contact hours or 1.4 continuing education units (CEU's).

Type of Activity: Knowledge

IACETDrug Information Association has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102.

As an IACET Authorized Provider, Drug Information Association of ers CEUs for its programs that qualify under the ANSI/IACET Standard. Drug Information Association is authorized by IACET to of er 1.4 CEUs for this program. Participants must attend the entire training course in order to be able to receive an IACET statement of credit. No partial credit will be awarded.

If you would like to receive a statement of credit, you must attend the entire meeting, sign-in at the DIA registration desk each day of the meeting, and complete the on-line credit request process through My Transcript at www.diahome.org. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on March 29, 2012.

Continuing Education Credit Allocation
Pharmacy:  
  Day 1: 286-000-12-044-L04-P; 7.5 contact hours or .75 CEUs
  Day 2: 286-000-12-045-L04-P;6.5 contact hours or .65 CEUs
IACET: 1.4 CEUs

 

This program is part of DIA's Certificate Program and is awarded the following:

  • Clinical Research Certificate Program: 8 Elective Units

For more information go to www.diahome.org/certificateprograms

Disclosure Policy:
It is Drug Information Association policy that anyone in a position to control the content of a continuing education activity must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and/or the educational activity, and (2) discussions of unlabeled or unapproved uses of drugs or medical devices.

Faculty disclosures will be included in the meeting materials.

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association.

Speakers and agenda are subject to change without notice.
Recording of any DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA.

To view DIA's Grievance Policy, please visit the CE page on DIA's website at www.diahome.org

Download Brochure

Program Agenda

Day 1 | March 14, 2012

7:15-8:15 AM Registration and Continental Breakfast

8:15-8:30 AM Welcome and Opening Remarks

Paul Pomerantz
Worldwide Executive Director
Drug Information Association (DIA)

8:30-10:30 AM Session 1 - CER Research Design: From Principles to Practice

Session Chairperson

Robert W. Dubois, MD, PhD
Chief Science Officer
National Pharmaceutical Council (NPC)

The advent of comparative effectiveness research (CER) raises a multitude of questions: what specific types of studies to fund, how to prioritize resources, how to involve stakeholders, and how to organize and oversee organizations that will sponsor and carry out the research. The complexities involved underscore the need for tenets or principles that can help govern and provide a framework to the entire CER enterprise. This session will be set up in three parts:

Part I: Comparative Effectiveness Policy Background, Perspectives, and Issues

Bryan R. Luce, PhD, MBA
Senior Vice President, Science Policy
United BioSource Corporation

Part II: Application of CER Principles by CER Researchers

Sean R. Tunis, MD, MSc
Director
Center for Medical Technology Policy

Part III: Reaction Panel: Views and opinions of developers and end users of CER data

Brian Sweet, RPh, MBA
Executive Director, Healthcare Alliances
AstraZeneca

10:30-10:45 AM Refreshment Break

10:45 AM-12:30 PM Session 2 - Heterogeneity of Treatment Effects in Comparative Effectiveness

Session Chairperson

Sheldon Greenfield, MD
Executive Co-Director
Health Policy Research Institute, Professor of Medicine
University of California, Irvine

This session will address the heterogeneity of treatment effects in comparative effectiveness research. The fact that patients with the same diagnoses respond differently to the same treatment has long been established. New information on the three major categories of causes, genetic/biologic, illness severity (or baseline risk), and extra-disease factors such as co-morbidity, socio-economic status, and non-adherence proneness, will be discussed. Inter-study heterogeneity and non-average patient responses will also be discussed.

Part I: Heterogeneity in Effectiveness Research

Sheldon Greenfield, MD
Executive Co-Director
Health Policy Research Institute, Professor of Medicine
University of California, Irvine

David Kent, MD, MSC
Associate Professor of Medicine
Institute for Clinical Research and Healthy Policy Studies
Tufts Medical Center

Part II: Application of Heterogeneity Concepts in Current CE Studies

Anirban Basu, PhD
Associate Professor
Dept. of Health Services, School of Public Health
Adjunct Associate Professor
Pharmaceutical Outcomes Research and Policy Program (PORPP)
University of Washington, Seattle

Sherine Gabriel, MD, MSc
Chair, PCORI Methodology Committee 
Professor of Medicine and of Epidemiology
Mayo Clinic

Part III: Reaction Panel: How companies view aspects of heterogeneity

Gilbert J. L'Italien, PhD
Executive Director
Global Health Economics & Outcomes Research
Bristol Myers Squibb

James F. Murray
Senior Director
Global Health Outcomes Center of Expertise
Eli Lilly and Company

12:30-1:30 PM Luncheon

1:30-3:30 PM Session 3 - Balancing Clinical, Health, and Cost Outcomes in Comparative Effectiveness Research

Session Chairperson

Craig A. Hunter, MPP, PGDP
Senior Research Scientist, US Health Technology Assessment
Eli Lilly and Company

Often what’s lost in comparative effectiveness discussions is how to balance the competing needs of various sectors of the health care industry. How patient-focused should research be, if doing so it limits the ability to extrapolate findings to larger population settings? Should costs be considered simultaneously with clinical effectiveness, or when comparative clinical effectiveness is not available?

This session will examine both the opportunities and challenges associated with trying to balance these, at times, competing demands within research. Attendees will also hear from leaders representing three key perspectives on this topic — patient-focused research, payer decision makers, and manufacturers, who will highlight both similarities and departures in how interrelated sectors approach these questions.

Part I: (Cost) Effectiveness: Challenges and Opportunities in Research

Peter Neumann, ScD
Professor of Medicine
Institute for Clinical Research and Healthy Policy Studies
Tufts Medical Center

Part II: Addressing These Needs: Three Perspectives on Research Demands from the Field

Jody Sheehan Garey, PharmD
Sr. Manager, Oncology Content, Clinical Content & Services
McKesson Specialty Health

Matt Rousculp, PhD, MPH
Director, Comparative Ef ectiveness Research
US Health Outcomes
GlaxoSmithKline

Joe V. Selby, MD, MPH
Executive Director
Patient-Centered Outcomes Research Institute (PCORI)

Part III: Discussions

3:30-3:45 PM Refreshment Break

3:45-5:15 PM Session 4 - Be Bold, Be Brave, Be Knowledgeable: A Practical Guide to Making the Case for CER in Your Company

Session Chairperson

James F. Murray
Senior Director
Global Health Outcomes Center of Expertise
Eli Lilly and Company

The best CER methods and applications are for not if researchers, and those that manage research, cannot successful make the case for their implementation within their own companies. This session will help those in attendance understand how to align and defend CER study designs with market needs in a way that will make communicating those research needs more effectively within their own management structures. Building on that foundation, panelists will offer insights into how that internal communication can occur, as well as share experiences from across industry with regard to how these efforts have occurred in the past.

Part I: Aligning Study Designs and Business Needs: A Practical Guide

Robert W. Dubois, MD, PhD
Chief Science Officer
National Pharmaceutical Council (NPC)

Part II: Making the Case for CER: "Once More Unto the Breach…"

Marc Berger, MD
Executive Vice President & Senior Scientist, Life Sciences
OptumInsight

Part III: Reaction Panel: Insight from industry

Lorrie Carr
Senior Director, US Market Access
Millennium Pharmaceuticals: The Takeda Oncology Company

Bart Barefoot
Director, Public Policy
GlaxoSmithKline

5:15-6:15 PM Reception

Day 2 | March 15, 2012

7:15-8:15 AM Registration and Continental Breakfast

8:15-8:30 AM Opening Comments

Dan Leonard
President
National Pharmaceutical Council (NPC)

8:30-10:30 AM Session 5 - From Evidence to Reality: The Role of CER in Guiding Healthcare Benefit Design and Service Delivery

Session Chairperson

Ross Maclean, MD
Vice President Health Services, The Americas
Bristol-Myers Squibb Company

Value-Based Benefit Design (VBBD) has emerged as an approach to align benefit design with healthcare services of proven value, factoring in patient behavior when facing out-of-pocket costs. VBBD attempts to reduce barriers to highvalue treatments and services (through lower costs to patients) while providing disincentives for the utilization of low value treatment and services (by means of higher costs to patients). The speakers will discuss the role of CER in informing the value of different treatments and what evidence they seek to inform VBBD program design.

Behavioral economics has emerged as a discipline to guide patient behaviors and is increasingly being applied to healthcare, including being embedded in care management, disease management and VBBD programs. To maximize value, CER evidence ought to align with the evidentiary needs of behavioral economics. The speakers will discuss the role of CER in informing behavioral economic interventions and what evidence they seek to inform the design of such interventions.

Sharing risk has an inherent appeal to the entity bearing the risk. With CER promising to deliver evidence of "what is best" there is the opportunity for producers of medical products to become involved in performance-based agreements for their products also known as risk-sharing, coverage with evidence development and managed entry schemes). Such agreements can be highly complex and are in their infancy across the US though more established in the EU. The speakers will focus on the role of CER in informing performance based agreements for medical products and what evidence they seek to inform such agreements.

Part I: Benefit Designer

Teresa B. Gibson, PhD
Director of Health Outcomes
Thomson Reuters

Part II: Behavior Influencer

Jordan Goldberg
CEO
stickK.com, LLC

Part III: Risk Bearer

James D. Chambers, PhD, MPharm, MSc
Project Director
The Center for the Evaluation of Value and Risk in Health
The Institute for Clinical Research and Health Policy Studies
Tufts Medical Center

10:30-10:45 AM Refreshment Break

10:45 AM-12:30 PM Session 6 - Delivering Evidence to the Market

Session Chairperson

Philip Ruff, PhD, CChem, MRSC, Csci
Global Pricing & Market Access
Millennium Pharmaceuticals: The Takeda Oncology Company

The best study designs and published findings won't hold much meaning if researchers and manufacturers are unable to translate key research findings in a market-friendly manner. While proper methods and rigorous approaches are necessary, equally important is the ability to apply well-developed evidence when responding to market demands for information. This two-part session will focus on various perspectives on these translation-based challenges and offer insights to both researchers and market-facing liaisons regarding considerations and approaches to maximizing the impact of evidence within this space.

Part I will focus not only on the market interactions, but also on considerations that should be taken into account while research plans are being created and executed in order to make market application more easily realized.

Part I: Insights

Christopher M. Marrone, PharmD
Senior Outcomes Liaison
Eli Lilly and Company

Additional Speaker Invited

Part II: Reaction Panel

Tamar R. Thompson
Group Vice President, Valuebased Purchasing & Health Policy
Jeffrey J. Kimbell & Associates

12:30-1:30 PM Luncheon

1:30-3:30 PM Session 7 - Life Cycle Case Studies: Applying CER Across the Healthcare Environment

Session Chairperson

Craig A. Hunter, MPP, PGDP
Senior Research Scientist, US Health Technology Assessment
Eli Lilly and Company

Panelists will take what has been shared over the past day and half and focus on case studies that demonstrate the synergies of the topics discussed in realworld settings and provide examples of the methods and approaches being applied to drug commercialization efforts.

3:30-4:00 PM Closing Remarks

Craig A. Hunter, MPP, PGDP
Senior Research Scientist, US Health Technology Assessment
Eli Lilly and Company

4:00 PM Meeting Adjourned

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association.

Speakers and agenda are subject to change without notice.
Recording of any DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA.

Registration & Travel

Special Offer

Register today and receive a complimentary Individual attendance for the archived DIA Webinar: The Patient-Centered Outcomes Research Institute’s National Priorities and Research Agenda, or choose a discounted Group Site registration for $399 or a Group Plus registration for $499. Email Carolyn Callahan or call 1.215.442.6194 to take advantage of this offer.

Registration Fees

Registration fee includes refreshment breaks, luncheons, and reception (if applicable), and will be accepted by mail, fax, or online.

Industry Fee US $700
   
Discount Fees  
Government (Full-time) US $400
Charitable Nonprofit/Academia (Full-time) US $500
   

Group Discounts:

Register 2 individuals from the same company and receive complimentary registration for a 3rd! All 3 individuals must register and prepay at the same time – no exceptions. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred.

Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia. To take advantage of this offer, please download this registration form for EACH of the three registrants from your company. Include the names of all three group registrants on each of the forms and return them together to DIA.

Register Now

Travel and Hotel

The most convenient airport is Ronald Reagan National Airport and attendees should make airline reservations as early as possible. The Renaissance Washington DC Hotel is holding a block of rooms at the reduced rate below until February 21, 2012, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

Single $259 Double $259

Attendees must make their own hotel reservations. Contact the Renaissance Washington DC Hotel by telephone at +1.800.HOTELS.1 OR +1.202.898.9000 and mention the DIA event. The hotel is located at 999 Ninth Street, NW, Washington, DC 20001, USA.

Cancellation Policy

On or before March 6, 2012
Administrative fee that will be withheld from refund amount:
Industry = $200
Government or Academia or Nonprofit = $100
Tutorial (if applicable) = $50

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

Participants with Disabilities

DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory- impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs.